Top Page
Oxford Nanopore Technologies PLC
(LSE:ONT)
Oxford Nanopore Technologies PLC (ONT) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford Nanopore Technologies PLC Business Overview & Revenue Model
Oxford Nanopore Technologies PLC Earnings Call Summary
Oxford Nanopore Technologies PLC Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 151.91M | 183.19M | 169.67M | 198.60M | 133.66M | 113.86M |
| Gross Profit | 86.63M | 105.39M | 90.48M | 123.81M | 73.19M | 46.88M |
| EBITDA | -101.49M | -93.09M | -105.71M | -49.67M | -140.34M | -55.07M |
| Net Income | -107.44M | -146.19M | -154.51M | -91.03M | -167.61M | -61.24M |
Balance Sheet | ||||||
| Total Assets | 671.70M | 742.05M | 777.06M | 823.89M | 841.87M | 281.21M |
| Cash, Cash Equivalents and Short-Term Investments | 331.80M | 338.37M | 270.05M | 476.19M | 618.47M | 80.86M |
| Total Debt | 44.10M | 45.96M | 41.66M | 34.10M | 24.80M | 23.63M |
| Total Liabilities | 148.30M | 155.71M | 133.21M | 130.33M | 137.89M | 95.28M |
| Stockholders Equity | 523.40M | 586.34M | 643.85M | 693.56M | 703.98M | 185.93M |
Cash Flow | ||||||
| Free Cash Flow | -84.45M | -123.83M | -164.59M | -91.62M | -84.64M | -90.28M |
| Operating Cash Flow | -74.11M | -109.89M | -137.30M | -49.39M | -53.83M | -63.81M |
| Investing Cash Flow | 50.76M | 15.03M | -61.79M | -65.79M | -161.99M | -26.94M |
| Financing Cash Flow | 72.15M | 73.58M | 64.73M | -13.71M | 622.90M | 158.58M |
Oxford Nanopore Technologies PLC Technical Analysis
Oxford Nanopore Technologies PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £96.66M | 12.73 | 64.40% | 8.33% | -3.61% | -6.35% | |
57 Neutral | £1.50B | -10.26 | -26.01% | ― | 22.03% | 20.01% | |
52 Neutral | £23.60M | -6.25 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | £225.26M | ― | ― | ― | ― | ― | |
41 Neutral | £89.04M | -5.79 | -209.34% | ― | 198.49% | -26.66% | |
38 Underperform | £11.80M | -0.29 | -407.49% | ― | 72.17% | 79.03% |
Oxford Nanopore Technologies PLC Corporate Events
Oxford Nanopore Technologies has reported a routine share transaction under its Share Incentive Plan involving Chief Financial Officer and director Nick Keher. Keher purchased 100 partnership shares at £1.50 each using gross salary, and, in line with the plan’s terms, the company issued a further 100 matching shares to be held by the plan trustee on his behalf. The disclosure, made under UK Market Abuse Regulation requirements, underscores ongoing use of equity-based incentives to align senior management with shareholder interests.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies reported a strong trading performance for 2025, expecting full-year revenue of approximately £223–224 million, up about 22% on a reported basis and 24% at constant currency, slightly ahead of its guidance. Growth was broad-based across regions, with all major geographies delivering more than 20% constant currency revenue increases, and across end markets, led by around 60% growth in Clinical revenue, 30% in BioPharma and 27% in Applied Industrial, while Research revenue rose about 15% despite funding pressures. Product demand was driven particularly by the PromethION range, which grew more than 40% year-on-year, underscoring continued adoption of its high-throughput platforms. The group also highlighted progress on its path to profitability and ended 2025 with roughly £302 million in cash and liquid investments, ahead of consensus expectations, providing a solid capital base to support its strategy. Oxford Nanopore plans to publish its preliminary results for the year ended 31 December 2025 on 2 March 2026, accompanied by a management presentation and Q&A.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £140.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc will engage with investors at two major January events, the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and the dbAccess UK & Ireland Conference in London, featuring a presentation, Q&A and investor meetings. The planned outreach, including a publicly accessible webcast of the J.P. Morgan session, underscores the company’s efforts to raise its visibility in the healthcare and life sciences investment community and to reinforce its positioning as a key player in real-time genomic and molecular analysis technologies.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has issued 190,696 new ordinary shares following the exercise of employee share options and the operation of certain remuneration schemes, with the new shares admitted to the FCA’s Official List and to trading on the London Stock Exchange’s main market under the company’s existing block listing facility. Following this allotment, Oxford Nanopore’s issued share capital stands at 966,057,025 ordinary shares with no treasury shares held, establishing the updated total voting rights figure that shareholders must use to assess disclosure thresholds under UK transparency rules and leaving headroom for the admission of a further 6,468,179 shares under the current block listing.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC announced a transaction involving the Share Incentive Plan (SIP) for its Chief Financial Officer, Nick Keher. On December 12, 2025, 118 ordinary shares were purchased on behalf of Keher, with an equal number of matching shares issued under the SIP. This move aligns with the company’s obligations under the UK Market Abuse Regulation, potentially impacting stakeholder confidence and reinforcing the company’s commitment to employee investment.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has engaged with major shareholders following its 2025 AGM to understand their concerns regarding a specific resolution. The company is committed to refining its strategic planning to maximize long-term value, and has appointed Francis Van Parys as CEO to lead the next phase of growth and enhance its commercial strategy.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £128.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc has announced the appointment of Francis Van Parys as the new Chief Executive Officer, effective March 2, 2026. Van Parys, who brings extensive experience from leading roles at Radiometer, Cytiva, and GE Healthcare, will succeed Gordon Sanghera, the company’s founding CEO. This leadership transition is expected to drive the next phase of growth for Oxford Nanopore, leveraging Van Parys’ expertise in scaling innovation-driven businesses. The company anticipates continued expansion and innovation under his leadership, aiming to enhance operational execution and deliver value to stakeholders.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £128.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC announced the issuance of 381,797 ordinary shares following the exercise of options and remuneration schemes, which have been admitted to trading on the London Stock Exchange. This increases the company’s issued share capital to 965,866,329 ordinary shares, impacting shareholder voting rights and potentially influencing market perceptions of the company’s growth and financial strategies.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £150.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies announced its participation in several investor conferences in December, including the Citi 2025 Global Healthcare Conference, the 37th Annual Piper Sandler Healthcare Conference, and the Berenberg European Conference. These events will feature analyst-led discussions and investor meetings, providing the company an opportunity to engage with stakeholders and potentially strengthen its market position.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £150.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC announced a transaction under its Share Incentive Plan (SIP) involving Nick Keher, the company’s Chief Financial Officer. On 12 November 2025, Keher was awarded 104 Partnership Shares, purchased at £1.44 each, and 104 Matching Shares, issued at no cost, as part of the company’s efforts to align employee interests with corporate performance. This transaction, conducted on the London Stock Exchange, reflects the company’s commitment to incentivizing its management team and could enhance stakeholder confidence in the company’s governance practices.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has postponed its virtual investor event due to the ongoing CEO succession process, while reaffirming its full-year 2025 revenue growth guidance at the top end of 20-23%. This decision reflects the company’s strategic focus on leadership transition while maintaining strong financial performance expectations, which may reassure stakeholders about its stability and future direction.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC announced the issuance of 1,704,751 ordinary shares following the exercise of options and remuneration schemes, which are now listed on the London Stock Exchange. This increases the company’s total voting rights to 965,484,532, impacting shareholder calculations under FCA rules.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.